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The second extracellular loop (ECL2) domain of CC-chemokine receptor 5 (CCR5) has been proposed as a specific target
site for therapeutic agents aimed at blocking CCR5-dependent entry by human immunodeficiency virus type I (HIV-1). We
have adapted two CCR5-using HIV-1 isolates, prototypic JR-CSF, and a primary isolate, 11-121, to replicate in vitro in the
presence of high concentrations of a monoclonal antibody (MAb 2D7) specific for the CCR5 ECL2 domain. The 75% inhibitory
concentrations (IC75) for the two 2D7-adapted isolates were approximately 100-fold higher than those for corresponding
control isolates passaged without the MAb. Adapted isolates did not acquire the ability to use CXCR4, CCR3, or CCR1. Env
clones derived from MAb 2D7-adapted JR-CSF showed several gp120 mutations that were not found in any of the control
JR-CSF clones. The in vitro observations suggest that CCR5-using HIV-1 strains might also be able to adapt in vivo to evade
an ECL2-blocking therapeutic agent. © 2001 Academic Press
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CCR5, the seven-transmembrane domain, G-coupled
receptor for chemokines RANTES, MIP-1a, and MIP-1b,
is the principal coreceptor for the nonsyncytium-inducing
(NSI), macrophage-tropic (M-tropic) strains of human im-
munodeficiency virus type I (HIV-1), irrespective of env
genetic subtype (Alkhatib et al., 1996; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;
Zhang et al., 1996). It is these strains that are usually
associated with transmission of infection and early dis-
ease.
There are three sets of observations that, together,
indicate that CCR5 would be a highly suitable target
against which to develop inhibitors of the CCR5/HIV-1
interaction to block entry and thereby treat and/or pre-
vent HIV-1 infection. First, the absence of cell surface
CCR5 expression caused by homozygosity for the natu-
rally occurring D32ccr5 allele (Liu et al., 1996; Wu et al.,
1997b) is associated with resistance to in vitro infection
of CD41 cells with CCR5-using (R5) HIV-1 (Dragic et al.,
996; Paxton et al., 1996; Aarons et al., 1997). Moreover,
32ccr5 homozygosity confers considerable, although
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382ncomplete, protection against acquisition of HIV infec-
ion (Balotta et al., 1997; Biti et al., 1997; O’Brien et al.,
997; Theodorou et al., 1997). This protection is manifest
mong Caucasians as an underrepresentation of
32ccr5 homozygotes in HIV seropositive populations
Dean et al., 1996; Huang et al., 1996), and an overrep-
esentation of these individuals among HIV-exposed but
ninfected people (Dean et al., 1996; Liu et al., 1996;
axton et al., 1996; Samson et al., 1996; Aarons et al.,
1997). Second, the D32ccr5 allele is highly prevalent
among Caucasians such that approximately 1 in 100 are
D32ccr5 homozygous (Martinson et al., 1997; Lucotte and
Mercier, 1998), yet this genotype appears to confer no
significant adverse phenotype (Nguyen et al., 1999).
Thus, it seems that this chemokine receptor is dispens-
able to human health. Finally, compared to individuals
homozygous for wild-type ccr5, individuals who are het-
erozygous for D32ccr5 have reduced cell surface expres-
sion of CCR5 (Wu et al., 1997b; de Roda Husman et al.,
1999a; Ometto et al., 1999), reduced susceptibility to
infection with R5 HIV-1 in a hu-PBL-SCID mouse model
(Picchio et al., 1997), reduced in vitro infectability of CD41
cells with R5 isolates (Wu et al., 1997b; Paxton et al.,
1998; Ometto et al., 1999), and progress to AIDS more
slowly (Dean et al., 1996; de Roda Husman et al., 1997b;
uang et al., 1996).
HIV-1 has a remarkable ability to evolve in response to
mmune and other pressures. The envelope glycoprotein
s the most variable of the structural proteins of HIV-1,
nd single or dual amino acid changes at certain sites,
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383ADAPTATION OF HIV-1 REPLICATION TO CCR5 BLOCKADEnotably within the third variable (V3) loop, have been
associated with differences in coreceptor use (Speck et
al., 1997). Evidence suggests that the gp120/CCR5 inter-
action involves multiple CCR5 domains (Atcheson et al.,
1996; Bieniasz et al., 1997; Rucker et al., 1996; Picard et
al., 1997) and that the amino-terminus (Nt) and second
extracellular loop (ECL2) are particularly important (Wu
et al., 1997a; Dragic et al., 1998; Farzan et al., 1998). A
monoclonal antibody (MAb), 2D7, which binds to a de-
terminant in the first half of CCR5 ECL2, acts as a recep-
tor antagonist and effectively blocks both chemokine
binding and HIV coreceptor activity (Wu et al., 1997a; Lee
et al., 1999). Therefore, the epitope recognized by this
antibody has been proposed as a particularly attractive
target for therapeutic agents aimed at disrupting the
gp120/CCR5 interaction (Wu et al., 1997a; Lee et al.,
1999). We have investigated whether, to overcome a
block to entry imposed by the presence of MAb 2D7,
envelopes from two different isolates will adapt to use
other regions of CCR5 for viral entry. We observed that, in
vitro, blockade of the CCR5 ECL2 resulted in reduced
sensitivity to infection inhibition by MAb 2D7. This adap-
tation was associated with the presence of mutations
disrupting a potential N-linked glycosylation site in the
gp120 V4 domain. Our observations indicate that HIV-1 is
able to evade the inhibition of viral entry mediated by
ECL2 blockade of CCR5, without acquiring the ability to
use other chemokine receptors.
RESULTS
Sensitivity of isolates to inhibition by MAb 2D7
MAb 2D7-adapted strains of HIV-1 JR-CSF and primary
isolate HIV-1 11-121 (designated JR-CSFad and 11-121ad)
were generated by serial passage in U87-CD4-CCR5
cells, in the presence of increasing concentrations of the
antibody (up to 90 and 75 mg/ml, respectively). Control
solates, designated JR-CSFcon and 11-121con, were
enerated by serial passage in the absence of antibody.
oth adapted isolates were considerably less inhibitable
y MAb 2D7 than their respective control isolates (Fig. 1).
ne hundred percent inhibition was not achieved for
ither of the 2D7-adapted isolates. For both control iso-
ates, the 75% inhibitory concentration (IC75) of MAb 2D7
as approximately 1 mg/ml, whereas for 11-121ad the
value approached 100 mg/ml. No significant inhibition of
JR-CSFad by MAb 2D7 could be demonstrated in either
of the two experiments using up to 100 mg/ml of the
antibody. Although the adapted viral stocks might have
been expected to contain residual antibody, the calcu-
lated maximum possible concentrations of MAb 2D7
(assuming no prior cellular absorption) in the assay wells
during the infection–inhibition experiments (0.6 mg/ml for
JR-CSFad and 0.24 mg/ml for 11-121ad) were within the
ranges at which the control isolates remain uninhibited.Coreceptor usage by control and adapted isolates
The capacity of the control and MAb 2D7-adapted
isolates to use different chemokine receptors as core-
ceptors for viral entry was assessed by measurement of
p24 production following infection of U87-CD4 cells ex-
pressing different chemokine receptor molecules. All JR-
CSF and 11-121 control and 2D7-adapted isolates used
CCR5, but not CCR1, CCR3, or CXCR4 (data not shown).
Sequencing of full-length env and accessory genes
vif, vpr, and vpu
To identify any highly prevalent Env mutation(s) in the
adapted JR-CSF isolate, as compared with the control
FIG. 1. Inhibition of control and monoclonal antibody (MAb) 2D7-
adapted JR-CSF and 11-121 HIV-1 isolates by MAb 2D7, which is
specific for the second extracellular loop of CCR5. The production of
p24 antigen was measured 5 days after infection (700 TCID50) of
duplicate cultures in the presence of a range of MAb 2D7 concentra-
tions. A shows the inhibition data for JR-CSFcon (closed circles) and
JR-CSFad (open circles). B shows the corresponding results for 11-
121con (closed squares) and 11-121ad (open squares).JR-CSF isolate, the full-length env genes, together with
the accessory genes vif, vpr, and vpu, were fully se-
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384 AARONS ET AL.quenced for both of these isolates. In each case, both
viral cDNA and proviral DNA were sequenced and the
results obtained were identical. The env, vif, vpr, and vpu
redicted amino acid sequences for JR-CSFcon were
dentical to those of JR-CSF in the GenBank database
Accession No. M38429) except for D164N in V2, and
hree mutations in gp41: R525A, R549K, and G666D.
hese four substitutions, and no others, were also
resent in the predicted amino acid sequences for JR-
SFad. Proviral env DNA samples derived from the two
1-121 isolates were similarly sequenced, but the exten-
ive sequence diversity of each (reflecting multiple com-
onent pseudospecies) precluded any useful compari-
on. Limiting dilution PCR was not performed.
R-CSF env clone gp120 [C1 to C5] sequences
Complete env genes were amplified from JR-CSF
DNA or proviral DNA by PCR and cloned into an ex-
ression vector. The functionality of each Env protein
as assessed in a cell-fusion assay. Figure 2 shows the
redicted C1–C5 amino acid sequence data for 10 func-
ional JR-CSF env clones aligned with the sequence for
R-CSF in the GenBank database (Accession No.
38429). All functional JR-CSF clones sequenced, in-
luding one derived from the original peripheral blood
ononuclear cells (PBMC) isolate (not shown), featured
D164N mutation in the V2 domain. Among the seven
dapted clones, there were two pairs having identical
1–C5 sequences: clones ad2.7 and ad3.2 showed no
utations other than the D164N already noted, and
lones ad2.2 and ad4.10 (the other identical pair, referred
o as ad2.2[4.10] hereafter) had additional mutations in
1, V2, C2 (disrupting a potential N-linked glycosylation
ite), V4 (disrupting a further potential N-linked glycosyl-
tion site), and C4. Strikingly, although no consistent
ifference(s) from the database/original/control se-
uences was seen in the five different gp120[C1–C5]
D7-adapted sequences, four of five (clones ad2.1,
d2.2[4.10], ad3.5, and ad3.9) showed disruption of a
otential N-linked glycosylation site in V4 (N403D or
405I). Neither of these mutations was found in any of six
ontrol clones (including three clones that were nonfunc-
ional in the cell-fusion assay, but which are also shown
n Fig. 2).
nalysis of gp120/p24 antigen ratios on control and
dapted JR-CSF and 11–121 isolates
To investigate the possibility that control and adapted
iruses differ in terms of expression levels of gp120,
ean gp120/p24 antigen ratios were measured for each
f the four isolates. Mean gp120/p24 antigen ratios ob-
ained were similar to those previously reported for mo-
ecularly cloned HIV-1 viruses cultured in PBMC (O’Brien
t al., 1994). The mean (SD) gp120/p24 antigen ratios for
R-CSFcon and JR-CSFad were 0.2026 (0.054) and 0.10010.023), respectively. The corresponding values for 11-
21con and 11-121ad were 0.4439 (0.013) and 0.2214
0.021). Thus, the values for the two 2D7-adapted isolates
ere approximately twofold lower than the ratios for their
espective control isolates. A difference of this magni-
ude is thought unlikely to be of biological significance.
DISCUSSION
The propensity for drug-resistant viral escape mutants
o arise is well recognized both in vivo (Condra et al.,
995) and in vitro (Gao et al., 1992). Similarly, HIV adapts
to replication in the presence of neutralizing antibodies
in vivo (Albert et al., 1990) and in vitro. In vitro, adaptation
has been clearly demonstrated for neutralizing sera
(Reitz et al., 1988; McKeating et al., 1993) and for MAbs
specific for the V3 loop domain (McKeating et al., 1989;
Masuda et al., 1990; Sirko and Ehrlich, 1996; Yoshida et
al., 1997), the V2 loop (Yoshiyama et al., 1994), and the
CD4-binding site (Mo et al., 1997). In addition, there is
increasing evidence that HIV evades the CTL response
in vivo by accumulating amino acid replacements within
CTL epitopes (Goulder et al., 1997). Thus, HIV is ex-
tremely adaptable in the face of selection pressures. The
interaction between envelope gp120 and the cell surface
coreceptors that mediate viral entry is a target for drug
development, and consequently the possibility of HIV
adaptation to this mode of inhibition should be antici-
pated.
De Vreese et al. (1996) have demonstrated in vitro
adaptation of the CXCR4-using (X4) HIV-1 NL4–3 molec-
ular clone to blockade of CXCR4 by members of the
bicyclam class of antiviral compounds, and recombina-
tion experiments with overlapping parts of the envelope
gene indicated that multiple mutations in gp120 were
necessary to confer the bicyclam-resistant phenotype. In
a similar study, adaptation of HIV-1 NL4–3 to the natural
ligand of CXCR4, stromal cell derived factor (SDF)-1a,
as associated with several mutations in gp120, but the
echanism of this adaptation was not investigated fur-
her (Schols et al., 1998). Thus, in vitro adaptation of X4
isolates to CXCR4 blockade occurs and appears to be
env mediated, but the phenomenon is of limited signifi-
cance in that most of the primary isolates associated
with person-to-person transmission of infection and early
disease use CCR5 rather than CXCR4.
Acquisition of a syncytium-inducing phenotype (corre-
sponding to CXCR4 usage) by a CCR5-using (R5) molec-
ular clone, 168.1, in the absence of any drug or exoge-
nous blocker of the gp120/coreceptor interaction has
been demonstrated after prolonged culture in lymphoid
cells (Este et al., 1999). Meanwhile, Mosier et al. (1999)
have reported on a study in which hu-PBL-SCID mice
were infused with highly potent RANTES analogues
AOP-RANTES or NNY-RANTES and challenged with a R5
HIV-1 242H molecular clone (Mosier et al., 1999). This R5
ted by
385ADAPTATION OF HIV-1 REPLICATION TO CCR5 BLOCKADEisolate needs only a single amino acid substitution to
become R5X4, and only three changes to become X4. In
four of four experimental animals given AOP-RANTES,
the viral load was reduced but HIV-1 infection neverthe-
less supervened, while NNY-RANTES prevented HIV-1
infection in 6 of 10 animals. The coreceptor usage of
FIG. 2. Predicted gp120 C1–C5 envelope amino acid sequences of c
in italics were nonfunctional in a cell–cell fusion assay and were seque
HXB2 that are involved in direct contact with CD4 are denoted by [¥] (Kw
by .90% without significantly affecting (,50%) sCD4 binding are deno
N-linked glycosylation sites.viruses recovered from the mice that became infected
was tested and the V3 domains of these isolates weresequenced. NNY-RANTES, but not AOP-RANTES, was
found to select for coreceptor switch variants, and the
acquisition of CXCR4 usage was associated with three
V3 loop amino acid substitutions. Neither cloning nor
site-directed mutagenesis studies were carried out to
confirm the phenotype conferred by these V3 loop mu-
and MAb 2D7-adapted HIV-1 JR-CSF env clones. (Clones represented
ly across V3 to V5.) Residue positions corresponding to those in HIV-1
al., 1998). Those positions that affect HIV-1 YU2 gp120 binding to CCR5
§ (Rizzuto et al., 1998). Positions shown as NxS or NxT are potentialontrol
nced on
ong ettations. Although these two studies indicate that R5 iso-
lates can acquire env-mediated CXCR4 usage in vitro
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386 AARONS ET AL.and in the hu-SCID mouse model, the significance of
these observations is uncertain as there are as yet un-
defined counterselective pressures that tend to favor
CCR5 usage by viruses in vivo and prevent outgrowth of
XCR4-using viruses.
In the present study, we report on the adaptation of R5
IV-1 to the blockade of viral entry imposed by a mono-
lonal antibody directed against the second extracellular
oop of the coreceptor CCR5, MAb 2D7, in the absence of
ny other chemokine molecule that might serve as a
oreceptor. Thus, the experimental conditions were set
o as to examine whether MAb 2D7 adaptation could
ccur in the absence of switching coreceptor usage. The
edian inhibitory concentrations (IC50) for the two 2D7-
adapted isolates were approximately 100-fold higher
than those for the corresponding control isolates, one of
which was a primary clinical isolate rather than a proto-
typic molecular clone, but there was no acquisition of
CXCR4 or CCR3 usage. Maeda et al. (2000) have dem-
onstrated adaptation of R5 JR-FL to growth in the pres-
ence of CCR5 ligand MIP-1a. No acquisition of CXCR4
usage was observed, but the MIP-1a IC50 for the adapted
JR-FL isolate was only fourfold higher than that of the
wild-type isolate. The reduced sensitivity to b-chemo-
ines was conferred by a V166M mutation in the V2
egion of gp120, together with another mutation, S303G,
n the V3 loop.
The crystal structure of a ternary complex comprising
IV-1 gp120 core, a two-domain fragment of CD4, and
7b Fab (which recognizes a CD4-induced epitope) hav-
ng recently been solved, a highly conserved gp120
tructure, has been proposed to be critical for binding of
5 HIV-1 to CCR5 (Rizzuto et al., 1998). However, the
nteraction between the HIV-1 envelope oligomers, CD4,
nd coreceptor molecules is dependent on cooperation
etween multiple gp120 and gp41 domains, including
egions not generally considered typical tropism deter-
inants. Consequently, while the adaptation of HIV-1
solates to blockade of CCR5 ECL2 observed in the
urrent study is highly likely to be env mediated, verifi-
ation of this will require analysis of the MAb 2D7 sen-
itivity of Env-pseudotyped reporter viruses.
The mechanism of MAb 2D7 adaptation has not been
lucidated in this study. It could involve reduced CD4
ependence, altered CCR5 domain use, or increased
ffinity of gp120/CCR5 interaction. It is unlikely to be
xplained by a higher gp120 spike density on the puta-
ively 2D7-adapted virions enhancing the avidity of the
irus/cell-surface interaction, as measured spike densi-
ies were approximately twofold lower for the 2D7-
dapted isolates than with the control isolates, and this
mall magnitude of difference is unlikely to be of biolog-
cal significance. Nevertheless, the observation of adap-
ation to blockade of CCR5 ECL2 in itself has implica-
ions for development of antiretroviral therapeutic agents
e
that block CCR5: it will be important to ascertain whether
hese compounds also provoke HIV adaptation.
MATERIALS AND METHODS
iruses and antibodies
Two R5 HIV-1 isolates were studied. Stocks of 11-121,
primary isolate from the Ariel Project for the prevention
f HIV transmission from mother to infant (Cao et al.,
997), and JR-CSF, a prototypic R5 strain, were expanded
y single passage on double-batched phytohemaggluti-
in/IL2-stimulated PBMC. Murine anti-human CCR5
Abs 2D7 and 3A9 were generated and characterized
s previously described (Wu et al., 1997a). The anti-CCR1
Ab 2D4 was a kind gift of Dr. Charles Mackay and Dr.
hixin Qin at Millenium Pharmaceuticals, Inc.
ell lines
Human glial U87 cells stably transfected with human
D4 alone or together with human CCR5, CCR1, CCR3, or
XCR4 (a gift of Dr. Daniel Littman, New York University
edical Center) were maintained in Dulbecco’s minimal
ssential medium (DMEM) containing 10% fetal calf se-
um (FCS), L-glutamine, antibiotics, neomycin (G418; 500
mg/ml; Sigma), and (except for the U87-CD4 cells, which
express CD4 alone) puromycin (1 mg/ml; Sigma) and
ere split by trypsinization twice a week (Deng et al.,
996). Flow cytometry showed that the U87-CD4-CCR5
ell line comprises a homogeneous population of cells
xpressing high levels of both CD4 and CCR5, but no
XCR4 (data not shown). Moreover, these cells were not
nfectable with CXCR4-using (X4) isolate NL4-3. Flow
ytometry following indirect staining with MAb 2D7 at
7°C as compared with 4°C demonstrated that binding
f this antibody does not result in internalization of the
eceptor (data not shown).
daptation of viral isolates to MAb 2D7
Adaptation to MAb 2D7 was performed by serial pas-
age of the viral isolates in U87-CD4-CCR5 cells, in the
resence of increasing concentrations of the antibody. At
ach passage, a pair of U87-CD4-CCR5 monolayers (2 3
04 cells/well seeded 18–24 h earlier in 24-well tissue
ulture plates) were inoculated with the putatively
dapted isolate from the previous passage in the pres-
nce (2D71) or absence (2D72) of antibody. To ascer-
ain the volume of culture supernatant for inoculating
hese two fresh cultures, the extent of cytopathic effect at
ay 5 in the 2D71 culture of the previous passage was
sed. To determine whether to maintain or increase (by
–5 mg/ml) the MAb 2D7 concentration in the new 2D71
ulture, the difference in cytopathic effect between the
revious 2D71 and control 2D72 cultures at day 5 was
valuated. Cells were incubated with antibody (at twice
he desired final concentration) for 30 min at 37°C prior
t
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387ADAPTATION OF HIV-1 REPLICATION TO CCR5 BLOCKADEto addition of virus and, following addition of virus, the
culture volume was made up to 1 ml. One day later, the
monolayers were washed twice with 1 ml PBS/2% FCS
and the supernatant replaced with 1 ml fresh growth
medium. Owing to the limited availability of MAb 2D7, the
replacement growth medium was supplemented with
MAb 2D7 (at the appropriate concentration) only every
third or fourth passage. The concentration of MAb 2D7
used for the first passage was 5 mg/ml. At the twenty-
hird passage, for which the treatment concentrations of
D7 for JR-CSF and 11-121 were 90 and 75 mg/ml, re-
spectively, the culture volume was scaled up fivefold to 5
ml cultures in six-well plates. Culture supernatants were
harvested on day 4, and aliquots of the putatively
adapted isolates, designated JR-CSFad and 11-121ad,
were stored at 280°C. Control isolates were generated
by 10 serial passages of the original JR-CSF and 11-121
stocks in U87-CD4-CCR5 cells, in the absence of MAb
2D7. These control isolates were designated JR-CSFcon
and 11-121con.
Titration of control and MAb 2D7-adapted isolates on
U87-CD4-CCR5 cells
U87-CD4-CCR5 cells were seeded in 48-well trays at
104 cells per well in 500 ml culture medium. Growth
medium without puromycin or neomycin was used there-
after. The following day, culture supernatants were re-
placed with medium containing each of the viral stocks
in serial, six-replicate fivefold dilutions. A day later, the
cells were washed twice (1 ml growth medium) and their
supernatants replaced with 500 ml fresh medium. Cul-
tures were then incubated a further 4 days at 37°C.
Following two washes in PBS/2% FCS, monolayers were
fixed in ice-cold 1:1 acetone:methanol. HIV-1-infected
cells were detected by the addition of a murine MAb
directed against HIV-1 p24 antigen (culture supernatant
of hybridoma 183-H12-5C: NIH AIDS Reagent Program)
at 1:4 dilution; alkaline phosphatase-conjugated F(ab9)2
fragment donkey anti-mouse IgG (Jackson) at 1:200 dilu-
tion; and Fast Red alkaline phosphatase substrate
(Sigma). Monolayers were scored positive or negative
according to the presence or absence of stained foci,
and the median tissue culture infectious dose (TCID50) of
each isolate was calculated using the Spearman–Karber
formula.
Sensitivity of isolates to inhibition by MAb 2D7
U87-CD4-CCR5 cells were seeded in 48-well trays at
104 cells per well in 500 ml of growth medium. The
ollowing day, after 30 min preincubation with a range of
Ab 2D7 concentrations at 37°C, duplicate cultures
ere inoculated with 700 TCID50 (approximately 3000
focus forming units) of each isolate. The monolayers
were washed 24 h after infection with PBS/2% FCS, and
the appropriate concentration of antibody replaced infresh growth medium. The production of p24 antigen 5
days after infection was measured by ELISA (NIH AIDS
Vaccine Program).
Coreceptor usage by control and adapted isolates
The panel of U87-CD4 cells expressing different che-
mokine receptors (CCR1, CCR5, CCR3, CXCR4) and a
high CD4-expressing U87-CD4 clone were seeded in
duplicate at 104 cells/well in 500 ml growth medium.
Monolayers were infected with 700 TCID50 each of the
JR-CSF/11-121 control or 2D7-adapted isolates. The
monolayers were washed and the medium containing
input virus replaced with fresh growth medium 24 h after
infection. The p24 antigen content of culture superna-
tants was measured by ELISA 5 days after infection.
Generation of viral cDNA and proviral DNA
Viral RNA was obtained from viral stocks using Trizol
Reagent (Gibco) according to the manufacturer’s instruc-
tions, and cDNA was produced using ThermoScript re-
verse transcriptase (Gibco-BRL) and the primer RC-11aR
59TAGCTGCTGTATTGCTACTTGTGA. To generate proviral
DNA, U87-CD4-CCR5 cells were infected with the con-
trol, adapted, and original PBMC-cultured 11-121 and
JR-CSF isolates at a high multiplicity of infection. Eigh-
teen hours later, the cells were washed and harvested by
trypsinization. Proviral DNA was then extracted and pu-
rified using a DNA/RNA isolation kit (Amersham Interna-
tional) according to the manufacturer’s instructions.
Sequencing of full-length env and of accessory genes
vif, vpr, and vpu
Full-length env genes of JR-CSFcon and JR-CSFad,
together with the accessory genes vif, vpr, and vpu, were
sequenced. Viral cDNA and proviral DNA samples were
amplified independently by nested PCR. In each case,
platinum Taq DNA polymerase high fidelity (Gibco-BRL)
as used for the first round and non-high-fidelity plati-
um Taq DNA polymerase (Gibco-BRL) was used for the
second round. For env amplification, the outer primer
pair was RC-10F 59TGCTATTGTAAAAAGTGTTGC and
RC-11aR (as above), and the inner primer pair was RC-
12F 59TATGGCAGGAAGAATTCGAGACAGCGA and RC-
9R 59ATGTTTTTCTAGGTCTCGAGATACTGCTCC (Connor
et al., 1996). Automated sequencing was performed us-
ing each of the following five primers: RC-12F (as above);
M2AF (59TGGGCCACACATGCCTGTGTACC); ARP826F
(59CGCTAGGAATTCGGCCAGTAG - TATCAACTCAA);
JRSEQ1F (59ATCTTCAGACCTGGAGGAGGAGACATG),
and RC-9R (as above). Nested primers (Zhang et al.,
1997) were used for amplification of vif, vpr, and vpu
outer pair: AccoutF 59TTAAAAGAAAAGGGGGGATT-
GGGGG, AccoutR 59ATTCCAT-GTGTACATTGTACT; inner
pair: AccinF 59AGATAATAGTGACATAAAAGTAGTG-
CCAAGAAG, AccinR 59CCATAATAGACTGTGACCCA-
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388 AARONS ET AL.CAA). The same two inner primers, AccinF and AccinR,
were then used singly for sequencing. Predicted amino
acid sequences were derived using Editseq (v3.73,
DNASTAR Inc.) and aligned using MegAlign (v1.02,
DNASTAR Inc.).
Cloning and sequencing of JR-CSF isolates
Complete env genes were amplified from viral cDNA
or proviral DNA by PCR, using platinum Taq DNA poly-
erase high fidelity (Gibco-BRL) and the primers RC-12F
nd RC-9R (as above), which contain restriction sites for
coRI and XhoI, respectively (Connor et al., 1996). Env
enes were ligated into the mammalian expression vec-
or pcDNA3.1zeo(1) (Invitrogen) and transfected into
93T cells using LipofectAmine (Gibco-BRL). It was not
ossible to use the same strategy for cloning of 11-121
nv as the viral sequence contained an internal EcoRI
site. Expression of functional Env was assessed by co-
culture of the 293T transfectants with U87-CD4-CCR5
cells followed by fixation and staining of the monolayers
using the in-house focal immunoassay described above
with modification: the detection antibody was pooled
HIV-1 seropositive human sera (1:200 dilution) and the
conjugate was alkaline phosphatase conjugated F(ab9)2
fragment donkey anti-human IgG1IgM (Jackson). Func-
tionality of Env was indicated by the presence of stained
syncytia. Three functional JR-CSFcon and seven func-
tional JR-CSFad clones were sequenced (gp120[C1–C5])
using primers M2AF and ARP826F (as above).
Analysis of gp120/p24 antigen ratios on control and
adapted JR-CSF and 11-121 isolates
Mean gp120/p24 antigen ratios were measured for
each of the four isolates (Moore et al., 1990). Briefly,
intact viral particles were separated from soluble viral
antigens by S1000 gel fractionation and, following lysis
with a nonionic detergent (Igepal: Sigma), the gp120
content (Moore and Jarrett, 1988) and p24 antigen con-
tent (NIH AIDS Vaccine Program ELISA) of each fraction
was assayed. Determinations on each 2D7-adapted and
corresponding control isolate pair were performed simul-
taneously.
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